JP2018507210A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507210A5
JP2018507210A5 JP2017543828A JP2017543828A JP2018507210A5 JP 2018507210 A5 JP2018507210 A5 JP 2018507210A5 JP 2017543828 A JP2017543828 A JP 2017543828A JP 2017543828 A JP2017543828 A JP 2017543828A JP 2018507210 A5 JP2018507210 A5 JP 2018507210A5
Authority
JP
Japan
Prior art keywords
deuterium
compound
group
structural formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017543828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507210A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018222 external-priority patent/WO2016133989A1/en
Publication of JP2018507210A publication Critical patent/JP2018507210A/ja
Publication of JP2018507210A5 publication Critical patent/JP2018507210A5/ja
Pending legal-status Critical Current

Links

JP2017543828A 2015-02-18 2016-02-17 小胞モノアミン輸送体2のジメトキシフェニル系阻害剤 Pending JP2018507210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117654P 2015-02-18 2015-02-18
US62/117,654 2015-02-18
PCT/US2016/018222 WO2016133989A1 (en) 2015-02-18 2016-02-17 Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2

Publications (2)

Publication Number Publication Date
JP2018507210A JP2018507210A (ja) 2018-03-15
JP2018507210A5 true JP2018507210A5 (enExample) 2019-03-22

Family

ID=56692737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543828A Pending JP2018507210A (ja) 2015-02-18 2016-02-17 小胞モノアミン輸送体2のジメトキシフェニル系阻害剤

Country Status (12)

Country Link
US (1) US10722479B2 (enExample)
EP (1) EP3258926A4 (enExample)
JP (1) JP2018507210A (enExample)
AR (1) AR103728A1 (enExample)
BR (1) BR112017017673A2 (enExample)
CA (1) CA2976229A1 (enExample)
EA (1) EA201791839A1 (enExample)
IL (1) IL253901A0 (enExample)
MA (1) MA41557A (enExample)
MX (1) MX2017010567A (enExample)
TW (1) TW201630871A (enExample)
WO (1) WO2016133989A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852843B (en) 1984-05-15 1985-11-27 Warner Lambert Co Bevantolol preparation
US20090182057A1 (en) * 2006-05-26 2009-07-16 Auspex Pharmaceuticals, Inc. Deuterated aminoglycidal compounds
WO2008122010A1 (en) 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
US20100009950A1 (en) * 2008-06-30 2010-01-14 Auspex Pharmaceuticals, Inc. Substituted ethanolamines
CA2736409C (en) * 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100143287A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
BR112015031835B1 (pt) * 2013-06-19 2022-12-13 Som Innovation Biotech, S.L Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético

Similar Documents

Publication Publication Date Title
JP2012503010A5 (enExample)
JP2012524085A5 (enExample)
JP2010507585A5 (enExample)
JP2009539863A5 (enExample)
JP2009538359A5 (enExample)
JP2016529228A5 (enExample)
ES2633658T3 (es) Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
JP2009511481A5 (enExample)
TWI549692B (zh) 使心臟神經分布顯像之配位體
JP2010512343A5 (enExample)
US20100076087A1 (en) Methods of reduction of interpatient variability
US9526711B2 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
JP2009535405A5 (enExample)
US20100087455A1 (en) Substituted xanthine compounds
CA2631581A1 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
JPWO2007063824A1 (ja) 放射性ハロゲン標識有機化合物の前駆体化合物
US20220062268A1 (en) Pharmaceutical composition for the treatment of parkinson's disease
JP2022525148A5 (enExample)
JP2025509969A5 (enExample)
CA2653209A1 (en) Deuterated aminoglycidyl compounds
US20100286124A1 (en) Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
WO2009151712A2 (en) Substituted phenylcyclohexylglycolates
US20110124914A1 (en) Optically active alpha-amino acid into which bsh is introduced and method for synthesizing the same
PL219269B1 (pl) Deuterowane pochodne katecholoaminy i ich zastosowanie oraz preparaty farmaceutyczne, zawierające te związki
RU2024129873A (ru) Дейтерированные аналоги пиррольных ингибиторов erk, их синтез и промежуточные соединения